FDA Approves Asthma Indication for Dupixent® (dupilumab)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/5/2026

1. ZS
2. LULU
3. IOT
4. SPY
5. PATH
6. DOCU
7. ASAN
8. NVDA
9. CIEN
10. GWRE

Go back to FDA Approves Asthma Indication for Dupixent® (dupilumab)
Regeneron (NASDAQ: REGN) Delayed: 827.72 -15.75 (1.87%)
Previous Close $843.47    52 Week High $592.36 
Open $840.05    52 Week Low $325.35 
Day High $841.54    P/E 217.25 
Day Low $825.83    EPS $3.81 
Volume 561,167